No profile data available.
NeuroPace, Inc. (NPCE) is a healthcare company in the targeted healthcare equipment industry, based in Mountain View, United States, with about 220 full-time employees.
It reported revenue of $99.99 million for fiscal year 2025, up 25.1% from fiscal year 2024, and net income of -$21.47 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $22.83 million, down 3.0% from a year before. United States was its largest region in fiscal year 2025, with 99% of revenue. Its market capitalization was $434.89 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
NeuroPace reported $99.99 million in revenue for fiscal year 2025, up 25.1% from $79.91 million in fiscal year 2024. In Q2 2026 revenue was $22.83 million.
United States: 99% of revenue by region in fiscal year 2025, followed by Foreign (1%).
$434.89 million as of October 9, 2026.
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Tactile Systems Technology, Inc. (TCMD), Sight Sciences, Inc. (SGHT), BrainsWay Ltd. (BWAY), CapsoVision, Inc. (CV).